Cynata Therapeutics (CYP.AX) Osake Kurssi
Cynata Therapeutics Kurssi
Viimeisten 19 vuoden aikana Cynata Therapeuticsn liikevaihto kasvoi 11,7 % vuodessa ja ylsi 1,71 M AUD:een. Cynata Therapeuticsn nettomarginaali −531,0 % on laskenut verrattuna −70,1 %:iin muutama vuosi sitten.
Cynata Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Cynata Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Cynata Therapeutics -osakkeesta
Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.
Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.
Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.
Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.
Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.
Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.
5 analyytikkoa arvioi tällä hetkellä Cynata Therapeutics-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Cynata Therapeutics-osake noteerataan hintaan 0,01 EUR (0,01 AUD).
Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.
liikevaihto Cynata Therapeutics on 1,71 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Cynata Therapeutics on −9,09 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Cynata Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,29. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cynata Therapeutics-osakkeen arvostusta.
Cynata Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,53. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cynata Therapeutics-osakkeen arvostuskennuslukuna.
Cynata Therapeutics:n Eulpool-laatuscore on 2/10.
Cynata Therapeutics:n ISIN on AU000000CYP7. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Cynata Therapeutics:n WKN on A1W8VE. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Cynata Therapeutics:n ticker on CYP.AX. Tämä pörssinoteeraus käytetään Cynata Therapeutics-osakkeiden kauppaan pörssissä.
Cynata Therapeutics osake
Cynata Therapeutics vertaisryhmä
Cynata Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Cynata Therapeutics:sta
Meidän osakeanalyysimme Cynata Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Cynata Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: